Journal of Antimicrobial Chemotherapy, Vol 42, 253-256, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
MH Nguyen and CY Yu
We compared the in-vitro activity of fluconazole, itraconazole,
ketoconazole and voriconazole against 67 blood isolates of Candida spp.
exhibiting a wide range of fluconazole MICs (0.125 to >64 mg/L).
Voriconazole was the most potent in vitro, followed by itraconazole,
ketoconazole and fluconazole. Itraconazole and voriconazole had in- vitro
activity against fluconazole-susceptible and -resistant candida isolates.
Higher itraconazole and voriconazole MICs were observed in isolates
exhibiting higher fluconazole MICs, suggesting cross- resistance.
Itraconazole and voriconazole MICs of > or =16 mg/L were observed only
in Candida albicans and Candida tropicalis. Candida krusei and Candida
glabrata exhibited itraconazole MICs of 0.5-1 mg/L and voriconazole MICs of
0.25-0.5 mg/L.
ORIGINAL ARTICLES
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole
Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA. nguyemt@medicine.ufl.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Takakura, N. Fujihara, T. Saito, T. Kudo, Y. Iinuma, S. Ichiyama, and the Japan Invasive Mycosis Surveillance Study Grou National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin J. Antimicrob. Chemother., February 1, 2004; 53(2): 283 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukuoka, D. A. Johnston, C. A. Winslow, M. J. de Groot, C. Burt, C. A. Hitchcock, and S. G. Filler Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1213 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M Pearson, P D. Rogers, J. D Cleary, and S. W Chapman Voriconazole: A New Triazole Antifungal Agent Ann. Pharmacother., March 1, 2003; 37(3): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Mann, R. M. Parmegiani, S.-Q. Wei, C. A. Mendrick, X. Li, D. Loebenberg, B. DiDomenico, R. S. Hare, S. S. Walker, and P. M. McNicholas Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14{alpha}-Demethylase Antimicrob. Agents Chemother., February 1, 2003; 47(2): 577 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A Pacetti and S. P Gelone Caspofungin Acetate for Treatment of Invasive Fungal Infections Ann. Pharmacother., January 1, 2003; 37(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laverdiere, D. Hoban, C. Restieri, and F. Habel In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients J. Antimicrob. Chemother., July 1, 2002; 50(1): 119 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. PELLETIER, L. LORANGER, H. MARCOTTE, and E. DE CAROLIS Voriconazole and fluconazole susceptibility of Candida isolates J. Med. Microbiol., June 1, 2002; 51(6): 479 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Manavathu, J. L. Cutright, D. Loebenberg, and P. H. Chandrasekar A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592) J. Antimicrob. Chemother., August 1, 2000; 46(2): 229 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Perea, G. J. Pennick, A. Modak, A. W. Fothergill, D. A. Sutton, D. J. Sheehan, and M. G. Rinaldi Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1209 - 1213. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. C. Chiou, A. H. Groll, and T. J. Walsh New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer Oncologist, April 1, 2000; 5(2): 120 - 135. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Lozano-Chiu, S. Arikan, V. L. Paetznick, E. J. Anaissie, and J. H. Rex Optimizing Voriconazole Susceptibility Testing of Candida: Effects of Incubation Time, Endpoint Rule, Species of Candida, and Level of Fluconazole Susceptibility J. Clin. Microbiol., September 1, 1999; 37(9): 2755 - 2759. [Abstract] [Full Text]
|
|